Establishment of a Monoclonal Antibody That Recognizes Cysteine-Rich Domain 1 of Human CD271

Shinkichi Morita, Mai Mochizuki, Rie Shibuya-Takahashi, Mao Nakamura-Shima, Tomoko Yamazaki, Takayuki Imai, Yukinori Asada, Kazuto Matsuura, Sadafumi Kawamura, Kazunori Yamaguchi, Jun Yasuda, Kazuo Sugamura, Yukio Katori, Kennichi Satoh, Keiichi Tamai

Research output: Contribution to journalArticlepeer-review

Abstract

CD271 is a common receptor for all neurotrophins that is localized to neurons, endothelial cells, and the basal layer of the epithelium in normal tissue. Recently, we and others reported that CD271 plays essential roles in the development of squamous cell carcinoma, especially in tumor-initiating cells. Since little is known about how CD271 regulates cancer cell initiation and proliferation, antibodies that recognize different domains of CD271 are needed to enable investigation. Therefore, this study aimed to develop an antihuman CD271 antibody by immunizing mice with a CD271 antigen produced by a baculovirus. The antibody was named hCD271mAb#13, and it recognized cysteine-rich domain 1 with a higher affinity than the commercially available antibody ME20.4. We determined that hCD271mAb#13 is suitable for flow cytometry, Western blotting, immunocytochemistry, and immunohistochemistry of formalin-fixed paraffin-embedded tissue. Use of hCD271mAb#13 for CD271 labeling could enable detailed analyses of cancer cell regulation and other biological processes.

Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Volume39
Issue number1
DOIs
Publication statusPublished - 2020 Feb
Externally publishedYes

Keywords

  • CD271
  • CRD1
  • immunohistochemistry

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Establishment of a Monoclonal Antibody That Recognizes Cysteine-Rich Domain 1 of Human CD271'. Together they form a unique fingerprint.

Cite this